The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.

The sector veteran also warned that the country is on the cusp of another wave of COVID-19 and needs to be very careful about large scale congregations during the upcoming festivities, pointing out that the jump in infections in Kerala was attributable to…

Adar Poonawalla’s Serum Institute is likely to buy additional stake in Biocon Biologics worth $500 million which will provide the much needed cash to Biocon to pay Mylan in a part equity, part cash deal for biosimilar business.

Biocon is calling the deal a transformational acquisition creating a world-leading biosimilars enterprise.

“This will enable us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government on its journey towards equitable access to diabetes care,” said Susheel Umesh, chief commercial officer, emerging markets, Biocon Biologics.

On the other sectoral front, the realty index added 1 percent, and auto, metal and pharma indices were up 0.5 percent each.